Direct-to-Consumer (DTC) Prescription Drug Programs
A Simple FAQ for Employers Several drug manufacturers now offer certain medications directly to patients at published cash prices. These […]
Q1 2026 Drug Updates: New FDA Approvals, Generics, and Biosimilars to Watch
By Beckie Fenrick, PharmD, MBA and Jason Peterson, RPh The first quarter of 2026 brought a steady flow of drug
What Accurate PBM Modeling Really Takes — And Why Clients Deserve More Than a Dashboard
By Greg Sanderson, VP of Analytics Over the last several years, pharmacy analytics has become increasingly visual. Dashboards, charts, and
Department of Labor Proposes New PBM Fee Disclosure Requirements for Self-Insured Health Plans
By: Beckie Fenrick, PharmD, MBA and Jason Peterson, RPh PBM compensation structures may soon face new federal transparency requirements. In
The Audit That Pays for Itself: Why Reviewing Your PBM’s Performance Isn’t Optional
By: Kevin Kobielski, President of Navion Pharmacy benefit managers often offer appealing guarantees—rebates, discounts, and price protections among some of them. But
Q4 2025 Drug Landscape: New FDA Approvals, Label Changes, and Biosimilars
By Beckie Fenrick, PharmD, MBA and Jason Peterson, RPh Q4 2025 brings meaningful FDA activity across high-cost therapeutic areas, along
Making Sense of MAP, PAP, and CAP Programs
By: Kevin Kobielski, President of Navion As specialty drug costs continue to rise, alternative funding programs like Manufacturer Assistance Programs
